Pharmacokinetics, dosimetry and toxicity of rhenium-188-labeled anti- carcinoembryonic antigen monoclonal antibody, MN-14, in gastrointestinal cancer

Journal of Nuclear Medicine

Volumn 39, Issue 1, 1998, Pages 34-42

  Juweid, Malik ^a   Sharkey, Robert M ^b   Swayne, Lawrence C ^b   Griffiths, Gary L ^b   Dunn, Robert ^b   Goldenberg, David M ^b  

^a GARDEN STATE CANCER CENTER   (United States)

^b NONE

Author keywords

Carcinoembryonic antigen; Gastrointestinal cancer; Monoclonal antibodies; Radioimmunotherapy; Rhenium 188

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY MN 14 RE 188; RHENIUM 188; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; CANCER IMMUNOTHERAPY; CLINICAL ARTICLE; DIGESTIVE SYSTEM CANCER; DOSIMETRY; DRUG DISTRIBUTION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; LEUKOPENIA; MALE; MAXIMUM PERMISSIBLE DOSE; PRIORITY JOURNAL; QUANTITATIVE DIAGNOSIS; THROMBOCYTOPENIA; TOXICITY TESTING;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; CARCINOEMBRYONIC ANTIGEN; COLONIC NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, RADIATION; FEMALE; HUMANS; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; RADIOIMMUNOTHERAPY; RADIOISOTOPES; RADIOTHERAPY DOSAGE; RHENIUM; TISSUE DISTRIBUTION;

EID: 0031950733     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Vriesendorp HM, Hepst JM, Germack MA, et al. Phase I-II studies of yttrium-labeled antiferritin treatment for end-stage Hodgkin's disease, including radiation therapy oncology group 87-01. J Clin Oncol 1991;9:918-928.
2. DeNardo SJ, DeNardo GL, O'Grady LF, et al. Pilot studies of radioimmunotherapy of B cell lymphoma and leukemia using I-131 Lym-1 monoclonal antibody. Antibody Immunoconj Radiopharm 1988;1:17-33.
3. Goldenberg DM, Horowitz JA, Sharkey RM, et al. Targeting, dosimetry, and radioimmunotherapy of B-cell lymphomas with iodine-131-labeled LL2 monoclonal antibody. J Clin Oncol 1991;9:548-564.
4. Juweid M, Sharkey RM, Markowitz A, et al. Treatment of non-Hodgkin's lymphoma with radiolabeled murine, chimeric, or humanized LL2, an anti-CD22 monoclonal antibody. Cancer Res 1995;55(suppl):5899s-5907s.
5. 131I]anti-B1 (anti-CD20) antibody. N Engl J Med 1993;329:459-465.
6. Press OW, Eary JF, Appelbaum FR, et al. Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. N Engl J Med 1993;329:1219-1224.
7. Epenetos AA, Munro AJ, Stewart S, et al. Antibody-guided irradiation of advanced ovarian cancer with intraperitoneally administered radiolabeled monoclonal antibodies. J Clin Oncol 1987;5:1890-1899.
8. De Nardo SJ, Mirick GR, Kroger LA, et al. The biologic window for ChL6 radioimmunotherapy. Cancer 1994;73(suppl):1023-1032.
9. Juweid M, Sharkey RM, Behr T, et al. Radioimmunotherapy of medullary thyroid cancer with iodine-131-labeled anti-CEA antibodies. J Nucl Med 1996;37:905-911.
10. 131I-labeled monoclonal antibody CC49 in colorectal cancer [Abstract]. Eur J Nucl Med 1992;19: 709.
11. Williams JR, Mayer RR, Yonggang Z, Quadri SM, Dillehay LE. Radiobiology and radioimmunotherapy: implications for clinical application. In: Goldenberg DM, ed. Cancer therapy with radiolabeled antibodies. Boca Raton, FL: CRC Press; 1994:33-43.
12. Knapp FF Jr, Callahan AP, Beets AL, Mirzadeh S, Hsieh B. Processing of reactor-produced tungsten-188 for fabrication of clinical scale alumina-based tungsten-188/rhenium-188 generators. Appl Radiat Isot 1994;45:1123-1128.
13. Knapp FF Jr, Lisic EJ, Mirzadeh S, Callahan AP, Rice DE. A new clinical prototype tungstcn-188/rhenium-188 generator to provide high levels of carrier-free rhenium-188 for radioimmunotherapy. In: Hoefer R, ed. Nuclear medicine in research and practice. Stuttgart, Germany: Schattauer Verlag; 1992:183-186.
14. Knapp FF Jr, Mirzadeh S, Zamora PO, et al. Rhenium-188 cost-effective therapeutic applications of a readily available generator derived radioisotope [Abstract], Nucl Med Commun 1996;17:268.
15. Knapp FF Jr, Mirzadeh S, Beets AL. Reactor production and processing of therapeutic radioisotopes for applications in nuclear medicine. J Radioanal Nucl Chem Lett 1996;205:93-100.
16. Primus FJ, Newell KD, Blue A, Goldenberg DM. Immunological heterogeneity of carcinoembryonic antigen: antigenic determinants on carcinoembryonic antigen distinguished by monoclonal antibodies. Cancer Res 1983;43:686-692.
17. Hansen HJ, Goldenberg DM, Newman ES, Grebenau R, Sharkey RM. Characterization of second-generation monoclonal antibodies against carcinoembryonic antigen. Cancer 1993;71:3478-3485.
18. Griffiths GL, Knapp FF Jr, Callahan AP, Chang CH, Hansen HJ, Goldenberg DM. Direct radiolabeling of monoclonal antibodies with generator-produced rhenium-188 for radioimmunotherapy. Cancer Res 1991;51:4594-4602.
19. 188Re use in radioimmunotherapy. Radioact Radiochem 1992;3:33-37.
20. Primus FJ, Kelley EA, Hansen HJ, Goldenberg DM. "Sandwich"-type immunoassay for carcinoembryonic antigen in patients receiving murine monoclonal antibodies for diagnosis and therapy. Clin Chem 1988;34:261-264.
21. 131I-labeled anti-carcinoembryonic antigen monoclonal antibody. Cancer Res 1990; 50(suppl):1039s-1042s.
22. Loevinger R, Berman M. A revised scheme for calculating the absorbed dose from biologically distributed radionuclide, MIRD Pamphlet No. 1, Revised. New York: Society of Nuclear Medicine; 1976.
23. Bigler R, Zanzonico PB, Leonard R, et al. Bone marrow dosimetry for monoclonal antibody therapy. In: Schlate-Stelson AT, Watson EE, eds. Proceedings of the Fourth International Radiopharmaceutical Dosimetry Symposium. Oak Ridge, TN: Oak Ridge Associated Universities; 1986:535-544.
24. Cloutier RV, Watson EE, Rohrer RH, et al. Calculating the radiation dose to an organ. J Nucl Med 1973;14:53-55.
25. Sharkey RM, Goldenberg DM, Murthy S, et al. Clinical evaluation of tumor targeting with a high-affinity, anti-carcinoembryonic-antigen specific, murine monoclonal antibody, MN-14. Cancer 1993;71:2081-2096.
26. Behr TM, Sharkey RM, Juweid ME, et al. Factors influencing the pharmacokinetics, dosimetry and diagnostic accuracy of radioimmunodetection and radioimmunotherapy of CEA-expressing tumors. Cancer Res 1996;56:1805-1816.
27. Yu B, Carrasquillo J, Milenic D, et al. Phase I trial of iodine 131-labeled COL-1 in patients with gastrointestinal malignancies: influence of serum carcinoembryonic antigen and tumor bulk on pharmacokinetics. J Clin Oncol 1996;14:1798-1809.
28. Juweid M, Behr TM, Sharkey RM, et al. Factors affecting the relationship between red marrow dose and myelotoxicity in patients receiving radioimmunotherapy with I-131 labeled anti-CEA monoclonal antibodies [Abstract]. J Nucl Med 1996;37:43.
29. 131I-labeled anti-CEA monoclonal antibodies [Abstract]. Tumor Targeting 1996;2:163.
30. Behr T, Sharkey RM, Juweid M, et al. Reduction of kidney uptake of radiolabeled monoclonal antibody fragments by cationic amino acids and their derivatives. Cancer Res 1995;55:3825-3834.